Pyxis Oncology is aiming to close out a transformative 2021 with an IPO. Having licensed a pair of antibody-drug conjugates (ADCs) from Pfizer and raised a megaround to develop them, Pyxis is now ...
PYXS has initiated dosing with PYX-201 in a phase 1 study, with preliminary results due in early 2024. PYXS expects to initiate dosing in a phase 1 study of PYX-106 in Q2'23, which could add ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback